Circulating DPP4 measurement may represent a novel cost-effective strategy for NAFLD/NASH risk stratification in dysmetabolic populations and a potential tool for monitoring disease’s progression and response to treatment in established NAFLD. Here, DPP4 is linked to metabolic dysfunction-associated steatohepatitis.